Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized, double-blind, active, controlled, multinational, multicentre, non-inferiority trial using carbetocin room temperature stable (RTS) for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally

Trial Profile

A phase III, randomized, double-blind, active, controlled, multinational, multicentre, non-inferiority trial using carbetocin room temperature stable (RTS) for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbetocin (Primary) ; Oxytocin
  • Indications Postpartum haemorrhage
  • Focus Therapeutic Use
  • Acronyms CHAMPION

Most Recent Events

  • 26 Jul 2021 According to Ferring Pharmaceuticals media release, Dr Shivaprasad Goudar, Professor of Physiology, J N Medical College & Director-Research, KLE Academy of Higher Education and Research, Belagavi, India is the Principal Investigator (India) for the CHAMPION clinical trial.
  • 27 Jun 2018 Results published in the Merck Media Release
  • 27 Jun 2018 According to Merck Media release, Results from this trial led by the World Health Organization (WHO) and conducted as part of a public-private collaboration with Ferring and Merck for Mothers, were published in the New England Journal of Medicine(NEJM).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top